7171 Rue Frederick Banting
Saint-Laurent, QC H4S 1Z9
Canada
514 332 4888
https://www.engene.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Jason D. Hanson Esq., J.D. | CEO & Director | 656.58k | N/A | 1969 |
Dr. Alex Nichols Ph.D. | President & COO | 504.44k | N/A | 1986 |
Dr. James C. Sullivan M.Sc., Ph.D. | Chief Scientific Officer | 524.29k | N/A | 1979 |
Dr. Anthony T. Cheung Ph.D. | Co-Founder & CTO | 341.75k | N/A | 1972 |
Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board | N/A | N/A | N/A |
Mr. David Ryan Daws | CFO & Head of Business Development | N/A | N/A | 1974 |
Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1981 |
Ms. Sharon Tan | VP of Project Management & Head of Program Management | N/A | N/A | N/A |
Dr. Richard P. Bryce MBChB, MFPM, MRCGP | Chief Medical Officer | N/A | N/A | 1957 |
Dr. Raj Pruthi M.D. | Senior VP of Urologic Oncology & Clinical Development | N/A | N/A | N/A |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.